SC-129

Genmab is licensing a second investigational anti-glycan monoclonal antibody from Scancell as part of an agreement inked between the two companies in 2022. Scancell, a British immunotherapy biotech, announced Wednesday that it will now receive an undisclosed upfront payment and low single-digit royalties on sales of any drug that comes out of the deal. The agreement is potentially worth up to $630 million if Genmab “develops and commercializes products across all defined modalities.” “The commercial license agreement follows an exclusive evaluation period, which further validates that our Glymab antibody platform can generate novel, differentiated, highly tumor specific antibodies for therapeutic development,” Scancell CSO Lindy Durrant said in a statement. In its latest financial report in September, Scancell told investors that SC129 (the first antibody that Genmab licensed in 2022) was on track for clinical development. The antibody is being considered as a treatment for pancreatic and gastrointestinal cancers. Scancell said then that it had enough cash to get through the third quarter of 2025. Genmab and Scancell first partnered in 2022 , when Genmab licensed an anti-glycan monoclonal antibody from the company. That deal also included an upfront payment of £5.3 million, in addition to $208 million for each commercialized therapy up to a maximum of $624 million.